Breaking News

Tweet TWEET

Zogenix and Battelle Extend DosePro Co-Marketing Partnership

Zogenix and Battelle Extend DosePro Co-Marketing Partnership

SAN DIEGO and COLUMBUS, Ohio, March 27, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc.
(Nasdaq:ZGNX), a pharmaceutical company commercializing and developing
products for the treatment of central nervous system disorders and pain, and
Battelle, the world's largest independent research and development
organization, today announced they have extended their co-marketing
partnership for the DosePro® needle-free drug delivery system through March
29, 2014. The partnership is focused on advancing out-licensing opportunities
for DosePro, with a focus on co-marketing the technology to potential
biopharmaceutical and government clients.

William Dunlevy, Vice President and General Manager, Process and Product
Development at Battelle, said, "Over the course of the past year, we have
worked closely with Zogenix to develop and implement a focused co-marketing
campaign that highlights key attributes of the DosePro needle-free delivery
system. We have received positive feedback regarding our study of DosePro
delivery of a monoclonal antibody and our self-injection survey of patients
with rheumatoid arthritis. These findings clearly demonstrate the benefits and
capabilities of the DosePro system. This has driven strong interest in the
DosePro technology from our clients, particularly in the delivery of highly
viscous formulations and biologics."

The campaign highlights a study by Battelle that demonstrates the ability of
the DosePro system to effectively deliver a monoclonal antibody therapeutic,
AbbVie's Humira® (adalimumab). The in vitro study showed that DosePro can
deliver Humira without incremental risk to protein denaturation and equivalent
biological integrity as compared to delivery by pre-filled syringe.

John Turanin, Vice President and General Manager, DosePro Technology, at
Zogenix, commented, "In the three years since its launch, we have produced
more than 2 million commercial units of our first commercial DosePro product,
SUMAVEL^® DosePro^®. The introduction of a needle-free delivery option has
reinvigorated growth of injectable sumatriptan, including from patients that
were previously not interested due to needle-phobia and/or the complexity of
delivery. We are pleased to provide an enhanced needle-free option for these
patients and look forward to continue working with Battelle to introduce the
benefits of the DosePro system to potential partners in the biopharmaceutical
and government sectors."

In accordance with the extension of their co-marketing partnership, Zogenix
and Battelle will continue to market DosePro, using the "Less is More"
campaign, to Battelle's clients in strategic product planning meetings, at
medical and industry conferences, in trade publications, and through other
marketing communications. The campaign, which was launched in July 2012,
emphasizes the simplicity and benefits of the DosePro technology and its
ability to provide instantaneous, needle-free, subcutaneous drug delivery. For
more information on licensing opportunities using the DosePro platform contact
Battelle at 1-800-201-2011 or solutions@battelle.org.

About DosePro®

The DosePro system is a first-in-class, easy-to-use drug delivery system
designed for self-administration of a pre-filled, single dose of sterile
liquid drug, subcutaneously, without a needle. The platform is currently used
by Zogenix's first commercial product, SUMAVEL DosePro^®. The Company believes
that DosePro offers several benefits to patients compared to other
subcutaneous needle-based delivery methods, and that it has the potential to
become a preferred delivery option for patients and physicians. These benefits
include less anxiety or fear due to the lack of a needle, easier disposal
without the need for a sharps container, no risk of needle stick injury or
contamination, an easy-to-use three step administration process, no need to
fill the device prior to use, reliable performance, discreet use and
portability. In several clinical trials and market research studies, DosePro
has been shown to be preferred by patients over conventional needle-based
systems.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville,
California, is a pharmaceutical company commercializing and developing
products for the treatment of central nervous system disorders and pain.
Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection)
Needle-free Delivery System, was launched in January 2010 for the acute
treatment of migraine and cluster headache. Zogenix's lead investigational
product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral,
extended-release formulation of various strengths of hydrocodone, without
acetaminophen, intended for administration every 12 hours for around the clock
management of moderate to severe chronic pain. In May 2012, Zogenix submitted
to the FDA a New Drug Application for Zohydro ER. Zogenix's second
investigational product candidate, Relday™, is a proprietary, long-acting
injectable formulation of risperidone for the treatment of schizophrenia; an
investigational new drug application was submitted to the FDA in May 2012.

About Battelle

As the world's largest independent research and development organization,
Battelle provides innovative solutions to the world's most pressing needs
through its four global businesses: Laboratory Management; National Security;
Health and Life Sciences; and Energy, Environment and Material Sciences. It
advances scientific discovery and application by conducting $6.5 billion in
global R&D annually through contract research, laboratory management and
technology commercialization. Headquartered in Columbus, Ohio, Battelle
oversees 22,000 employees in more than 130 locations worldwide, including
seven national laboratories which Battelle manages or co-manages for the U.S.
Department of Energy, the U.S. Department of Homeland Security, and a nuclear
energy lab in the United Kingdom.

Battelle also is one of the nation's leading charitable trusts focusing on
societal and economic impact, and actively supporting and promoting science,
technology, engineering and mathematics (STEM) education.

Forward-Looking Statements

Zogenix cautions you that statements included in this press release that are
not a description of historical facts are forward-looking statements. Words
such as "believes," "anticipates," "plans," "expects," "indicates," "will,"
"intends," "potential," "suggests," "assuming," "designed" and similar
expressions are intended to identify forward-looking statements. These
statements are based on the company's current beliefs and expectations. These
forward-looking statements include statements regarding the ability to
successfully out-license the DosePro technology. The inclusion of
forward-looking statements should not be regarded as a representation by
Zogenix that any of its plans will be achieved. Actual results may differ from
those set forth in this press release due to the risk and uncertainties
inherent in Zogenix's business, including, without limitation: difficulties in
identifying, negotiating, executing and carrying out strategic transactions
relating to DosePro and obtaining regulatory approval for other DosePro
products; risks associated with the development of a larger volume, second
generation version of the DosePro technology to accommodate drug formulation
volumes greater than 0.5 mL; the potential that earlier pre-clinical studies
may not be predictive of future pre-clinical or clinical results; and the
scope, validity and duration of patent protection and other intellectual
property rights for DosePro; the impact of any inability to raise sufficient
capital to fund ongoing operations; and other risks described in Zogenix's
filings with the Securities and Exchange Commission. You are cautioned not to
place undue reliance on these forward-looking statements, which speak only as
of the date hereof, and Zogenix undertakes no obligation to revise or update
this press release to reflect events or circumstances after the date hereof.
All forward-looking statements are qualified in their entirety by this
cautionary statement. This caution is made under the safe harbor provisions of
Section 21E of the Private Securities Litigation Reform Act of 1995.

SUMAVEL^®, DosePro^®, Relday^TM and Zohydro^TM ER are trademarks of Zogenix,
Inc.

SODAS^® is a trademark of Alkermes Pharma Ireland Limited.

HUMIRA® is a trademark of AbbVie.

                                     FPR

CONTACT: Zogenix Contacts:
        
         Investors
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com
        
         Media
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
        
         Battelle Contacts:
        
         Katy Delaney
         614.424.7208 | delaneyk@battelle.org
        
         T.R. Massey
         614.424.5544 | masseytr@battelle.org